Melodiol Global Health Limited

Melodiol Delivers Record Revenue Quarter With Group Sales Up 105%

Melodiol Global Health Limited (ASX:ME1, FRA:1X8) (‘Melodiol’ or ‘the Company’) is pleased to provide the following trading update for its group operations in the June quarter, where the Company reported a material acceleration in group revenues.


Highlights:

  • Unaudited net sales for the combined Melodiol group of $4.74m - 105% gain on last quarter and a 202% increase on the PCP
  • Q2 sales take H1 CY23 net sales to $7.06m – a 64% uplift on H1 CY22 (H1 CY22: $4.31m)
  • Revenue momentum highlighted by a material contribution from Health House International, a leading global supplier of medicinal cannabis, which was acquired in mid-Q2
  • Health House International revenues included in the total are from 16 May 2023 to 30 June 2023 only – Melodiol anticipates further growth will be realised from the division over the coming months
  • Strong contributions from other group subsidiaries expected to underpin further growth in H2 2023
The results were highlighted by strong quarterly growth across Melodiol’s two fully- owned subsidiaries, specialist medicinal cannabis distributor Health House International (‘HHI’) and Mernova Medicinal Inc. (‘Mernova’), a leading supplier of recreational cannabis products in the Canadian market.

For the June quarter, Melodiol reported preliminary net sales of A$4.74m, up 105% from the previous quarter (A$2.32m) and 202% higher than the prior year comparative period (A$1.57m). This takes unaudited sales for the first half of CY23 to $7.05m, which marks a 64% uplift on H1 CY22 (A$4.31m).

Group revenues in Q2 were boosted by the strong contribution from Health House International (based on revenue contributions to Melodiol from 16 May 2023 to 30 June 2023), which was integrated during the quarter after Melodiol closed the acquisition in May 2023 (refer ASX Announcement 16 May 2023).

The acquisition and smooth integration of HHI has materially expanded the scale and market penetration of Melodiol’s international operations. Leveraging its established market channels in Australia and the UK, HHI reported strong top-line growth in Q2 (refer ASX Announcement 3 July 2023) and is expected to underpin further operating momentum in the second half of the year.

Those results were accompanied by an equally strong quarter for Mernova in Canada, which delivered a 42% increase in sales on the PCP to round-out record half-year sales of A$3.095m (refer ASX Announcement 10 July 2023).

Across the group, the Q2 sales result represents another key milestone and continues to validate Melodiol’s stated strategy of seeking growth through targeted M&A that capitalises on the Board and management team’s unique understanding of the market forces underpinning the global cannabis industry.

With a record Q2 sales result, the Company is focused on consolidating its market momentum following the successful integration of HHI, and driving further growth in revenue and EBITDA across its core operating divisions.

Concurrently, Melodiol is maintaining a strategic focus on R&D and regulatory pathways for the application of novel treatments to complement its established revenue channels.

Ongoing work in this market was highlighted by a recent Letter of Intent (LOI) to enter an exclusive commercial relationship with Swiss pharmaceutical company Apotheke Dr. Hysek AG for the supply of GMP MDMA and synthetic psilocybin products to the Australian market (refer ASX Announcement June 9 2023).

Chief Executive Officer Mr William Lay said: “This group revenue result is particularly pleasing for Melodiol, and highlights the work carried out by the Board and management team to establish itself as a diversified supplier of best-in-class cannabis products across global markets.

“The material uplift in revenues on a quarter-on-quarter basis is further evidence of the group’s operating momentum, and sets the Company up for an exciting second half of the year following the integration of HHI in Q2. With revenue momentum now established, we look forward to providing more updates on both our trading operations along with our work as a first-mover in the market for novel treatment therapies that currently have an untapped addressable market.”


Click here for the full ASX Release

This article includes content from Melodial Global Health, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

Melodiol Global Health

Melodiol Global Health Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Melodiol Global Health

Melodiol Global Health


Keep reading...Show less
Cannabis leaf over map of Australia.

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.

Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will reach AU$3.73 billion in 2024 and grow at an annual rate of 3.22 percent, culminating in market volume worth AU$4.53 billion by 2029.

However, Australia’s cannabis industry is still young. Despite there being a strong case for a regulated market, which was outlined in a July 2024 report by the Penington Institute, recreational use is not legal and medical access remains limited and regulated. Yet, public support for legalisation is growing. YouGov data released in January 2024 showed that over half of Australians polled are in favour of decriminalising cannabis, and half of the respondents between the ages of 18 and 49 support legalising personal use.

In 2023, the Australian Greens, the country’s only seat-holding federal party in favour of legalisation, introduced the Legalising Cannabis Bill 2023, sponsored by the party’s leader Senator David Shoebridge. This was Australia’s first parliamentary effort to legalise cannabis.

Keep reading...Show less

Spinach® Is the Number One Cannabis Brand in Canada

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, is proud to announce that its award-winning brand Spinach® has risen to the best-selling cannabis brand in the Canadian market. 1 Spinach's market share outperformance represents Cronos' relentless commitment to quality, innovation, and bringing differentiated products to the competitive Canadian adult-use market.

Since launching in November 2018, Spinach has quickly become the preferred choice among new and seasoned adult consumers alike. The success of Spinach is bolstered by its best-selling and breakthrough portfolio of products, including ranking first in both edibles and flower. 1

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Hallandale Beach, Florida

New Broward County location will host grand opening celebration Friday, October 11 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Hallandale Beach, Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Partners with Black Buddha Cannabis to Launch Premium Products in Arizona and Pennsylvania

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing medical marijuana company in the U.S., today announces a partnership with Black Buddha Cannabis a purpose-driven and women-owned medical marijuana brand. The collaboration will introduce Black Buddha Cannabis products to Trulieve dispensaries in Arizona and Pennsylvania starting in October 2024 .

Products from Black Buddha's

Black Buddha Cannabis, founded by Roz McCarthy , CEO of Soaring High Industries and Minorities for Medical Marijuana, brings a unique approach to the medical marijuana industry with a focus on wellness and healing. McCarthy, a 30+ year healthcare industry veteran and a 2018 honoree in High Times' 100 Most Influential People, launched Black Buddha Cannabis after a traumatic brain injury that transformed her life and inspired her to explore the therapeutic benefits of medical marijuana.

Products from Black Buddha's "BLYSS" and "DREAM" lines of premium medical marijuana flower will be available in Trulieve stores throughout Arizona and Pennsylvania starting Friday, October 4 . Black Buddha products are curated for a blissful experience by focusing on terpene profiles and enhanced therapeutic effects that cater to a balanced lifestyle.

"We are incredibly excited to bring Black Buddha Cannabis to the vibrant markets of Arizona and Pennsylvania ," says Black Buddha Cannabis Chief Executive Officer Roz McCarthy . "Our brand is deeply rooted in wellness, and our mission is to help people feel better, whether they are part of the adult-use or medical marijuana community. We believe everyone deserves access to products that enhance their well-being, and we're thrilled to offer our carefully curated flower lines to these new markets."

Trulieve's partnership with Black Buddha Cannabis marks a significant milestone in expanding the Company's product offerings and supporting brands that align with Trulieve's commitment to wellness, innovation, and quality. This collaboration is expected to resonate with customers who seek premium medical marijuana crafted with intention and care.

"We are excited to welcome Black Buddha Cannabis to our product lineup," said Trulieve's Chief Executive Officer Kim Rivers . "Roz's inspiring story and her brand's dedication to healing through medical marijuana align perfectly with Trulieve's mission to provide high-quality, purpose-driven products to our customers."

Arizona and Pennsylvania will serve as the target markets for the initial launch of the partnership, a collaboration that underscores Trulieve's ongoing commitment to offering high-quality and innovative products that cater to the diverse needs of its customers.

For more information on Black Buddha Cannabis, please visit BlackBuddha.co . Visit Trulieve.com to find store locations, sign up for updates and shop for products online.

About Black Buddha Cannabis
Black Buddha Cannabis establishes a new paradigm for the industry as a black-owned, environmentally conscious, wellness-focused, and social equity-driven brand. Black Buddha Cannabis' premiere lifestyle and wellness products will be found at leading dispensaries across the country through state-by-state brand partnerships with manufacturers, cultivators, and operators. Currently available in Ohio , Nevada and Massachusetts , Black Buddha Cannabis expects to have products available in New Jersey in January 2025 . To learn more about Black Buddha Cannabis please visit http://blackbuddha.co .

About Trulieve
Trulieve is an industry-leading, vertically integrated medical marijuana company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to medical marijuana, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact  
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-partners-with-black-buddha-cannabis-to-launch-premium-products-in-arizona-and-pennsylvania-302263424.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2024/01/c1475.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Hudson, Florida

New Pasco County location will host grand opening celebration Friday, September 27 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., announced the opening of a new medical cannabis dispensary in Hudson, Florida .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Lake Worth, Florida

New Palm Beach County location will host grand opening celebration Friday, September 27 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Lake Worth, Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Melodiol Global Health

Melodiol Global Health Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×